Global Burden of Cutaneous Melanoma in 2020 and Projections to 2040.
Journal
JAMA dermatology
ISSN: 2168-6084
Titre abrégé: JAMA Dermatol
Pays: United States
ID NLM: 101589530
Informations de publication
Date de publication:
01 05 2022
01 05 2022
Historique:
pubmed:
31
3
2022
medline:
21
5
2022
entrez:
30
3
2022
Statut:
ppublish
Résumé
Despite many cases being preventable, cutaneous melanoma remains the most serious skin cancer worldwide. Understanding the scale and profile of the disease is vital to concentrate and reinforce global prevention efforts. To examine global patterns of cutaneous melanoma in 2020 and to provide projected estimates of cases and deaths by 2040. This population-based study used the GLOBOCAN 2020 database for global epidemiological assessment of new cases and deaths due to invasive melanoma. Age-standardized incidence and mortality rates were calculated per 100 000 person-years by country, world region, and 4-tier level of human development. Estimated numbers of cases and deaths were calculated for the year 2040. A worldwide total of 325 000 new melanoma cases (174 000 males, 151 000 females) and 57 000 deaths (32 000 males, 25 000 females) was estimated for 2020. Large geographic variations existed across countries and world regions, with the highest incidence rates among males (42 per 100 000 person-years) and females (31 per 100 000 person-years) observed in Australia/New Zealand, followed by Western Europe (19 per 100 000 person-years for males and females), North America (18 per 100 000 person-years for males, 14 per 100 000 person-years for females), and Northern Europe (17 per 100 000 person-years for males, 18 per 100 000 person-years for females). Melanoma continued to be rare in most African and Asian countries, with incidence rates commonly less than 1 per 100 000 person-years. Mortality rates peaked at 5 per 100 000 person-years in New Zealand, and geographic variations were less pronounced than for incidence. Melanoma was more frequent among males than females in most world regions. If 2020 rates continue, the burden from melanoma is estimated to increase to 510 000 new cases (a roughly 50% increase) and to 96 000 deaths (a 68% increase) by 2040. This epidemiological assessment suggests that melanoma remains an important challenge to cancer control and public health globally, especially in fair-skinned populations of European descent.
Identifiants
pubmed: 35353115
pii: 2790344
doi: 10.1001/jamadermatol.2022.0160
pmc: PMC8968696
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
495-503Commentaires et corrections
Type : CommentIn
Références
Eur J Cancer. 2004 Nov;40(16):2355-66
pubmed: 15519506
J Eur Acad Dermatol Venereol. 2014 Sep;28(9):1170-8
pubmed: 23962170
Br J Cancer. 2012 Feb 28;106(5):970-4
pubmed: 22294187
Aust N Z J Public Health. 2015 Oct;39(5):471-6
pubmed: 26437734
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Prev Med. 2016 Oct;91:294-298
pubmed: 27565055
J Invest Dermatol. 2015 Apr;135(4):1190-1193
pubmed: 25330295
Int J Cancer. 2019 Apr 15;144(8):1941-1953
pubmed: 30350310
Nat Genet. 2020 May;52(5):494-504
pubmed: 32341527
Am J Public Health. 2020 May;110(5):731-733
pubmed: 32191523
Cancer Epidemiol. 2016 Sep;44 Suppl 1:S100-S109
pubmed: 27034057
Lancet Public Health. 2019 Mar;4(3):e137-e147
pubmed: 30733056
IARC Monogr Eval Carcinog Risks Hum. 2012;100(Pt A):1-401
pubmed: 23189749
Expert Opin Pharmacother. 2019 Jun;20(9):1135-1152
pubmed: 31025594
Int J Cancer. 2012 Jan 1;130(1):170-8
pubmed: 21344376
Lancet Oncol. 2009 Aug;10(8):751-2
pubmed: 19655431
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Eur J Cancer. 2021 Jul;152:18-25
pubmed: 34062483
Lancet Oncol. 2017 Dec;18(12):1579-1589
pubmed: 29111259
Nat Genet. 1996 Jan;12(1):97-9
pubmed: 8528263
Eur J Cancer. 2015 Dec;51(18):2833-41
pubmed: 26589973
Melanoma Manag. 2014 Aug;1(1):75-84
pubmed: 30190812
Cancer Causes Control. 2002 Mar;13(2):175-82
pubmed: 11936824
Melanoma Res. 2020 Jun;30(3):279-285
pubmed: 30106842
JAMA Dermatol. 2020 Jan 1;156(1):57-64
pubmed: 31721989
Eur J Cancer. 2018 Mar;92:108-118
pubmed: 29395684
Int J Cancer. 2021 Apr 5;:
pubmed: 33818764
Int J Cancer. 2010 Dec 15;127(12):2893-917
pubmed: 21351269
Nat Rev Cancer. 2006 Jan;6(1):63-74
pubmed: 16372017
J Am Acad Dermatol. 2017 Jan;76(1):129-139.e10
pubmed: 27707591
Cancer Epidemiol Biomarkers Prev. 2005 Aug;14(8):2015-22
pubmed: 16103454
Cancer Res. 2006 Oct 15;66(20):9818-28
pubmed: 17047042
Lancet. 2018 Mar 17;391(10125):1023-1075
pubmed: 29395269
J Invest Dermatol. 2016 Jun;136(6):1161-1171
pubmed: 26902923
JAMA Dermatol. 2017 Feb 1;153(2):225-226
pubmed: 28002545
Eur J Cancer. 2005 Sep;41(14):2040-59
pubmed: 16125929
Int J Cancer. 2020 Sep 1;147(5):1391-1396
pubmed: 32067220
Cancers (Basel). 2020 Jul 07;12(7):
pubmed: 32645881
Int J Environ Res Public Health. 2021 Apr 15;18(8):
pubmed: 33920754
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30
pubmed: 26742998
Int J Cancer. 2013 Jan 15;132(2):385-400
pubmed: 22532371
Nat Genet. 1995 Nov;11(3):328-30
pubmed: 7581459
Cancer. 2004 Nov 1;101(9):2067-78
pubmed: 15372475
Br J Cancer. 2007 Jun 4;96(11):1772-7
pubmed: 17533392
IARC Sci Publ. 1992;(120):862-4
pubmed: 1284607
N Engl J Med. 2021 Jan 7;384(1):72-79
pubmed: 33406334
Int J Cancer. 2018 Sep 15;143(6):1305-1314
pubmed: 29659012
Melanoma Res. 1993 Dec;3(6):395-401
pubmed: 8161879
JAMA Dermatol. 2020 May 1;156(5):553-560
pubmed: 32211827
Front Immunol. 2019 Mar 19;10:453
pubmed: 30941125